References
- Lewenhaupt A, Ekman P, Eneroth P, Nilsson B, Nordstrom L. Tissue polypeptide antigen (TPA) as a prognostic aid in human prostatic carcinoma. Prostate 1985; 6: 285–91
- Lewenhaupt A, Ekman P, Eneroth P, Eriksson A, Nordström L. Serum levels of prostatic acid phosphatase (PAP), CA-50, neopterin, and of osteocalcin in patients with prostatic carcinoma. Scand J Clin Lab Invest 1985; 45: 75–80, Suppl 179
- Lewenhaupt A, Ekman P, Eneroth P, Eriksson A, Nilsson B, Nordström L. Serum levels of neopterin as related to the prognosis of human prostatic carcinoma. Eur Urol 1986; 12: 422–5
- Killian C S, Yang N, Emrich L J, et al. Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer. Cancer Res 1985; 45: 886–91
- Lewenhaupt A, Ekman P, Eneroth P, Kallner A, Nordström L. Tumor markers in human prostatic carcinoma. On optimation of reference values. Eur Urol 1990; 17: 7–11
- Killian C S, Emrich L J, Vargas F P, et al. Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. J Natl Cancer Inst 1986; 76: 179–85
- McNeal J E, Bostwick D G, Kindrachuk R A, Redwine E A, Freiha F S, Stamey TA. Patterns of progression in prostatic carcinoma. Lancet 1986; 1: 60
- Cox DR. Regression model and life-tables. J R Statist Soc B 1972; 34: 187–220
- Lewenhaupt A, Ekman P, Eneroth P, Nilsson B. Tumour markers as prognostic aids in human prostatic carcinoma. Br J Urol 1990; 66: 182–7